which facilitates incorporation into and out of specific genomic regions. Integrons contain collections of genes (gene cassettes) that are generally classified according to the sequence of the protein (integrase) that participate in their recombination function. They have the ability to integrate stably into regions of other DNAs, where they deliver, in a single exchange, multiple new genes, particularly drug resistance. The super-integron, which consists of hundreds of genetic cassettes (accounting for about 3% of the host genome), differs from other integrons. These elements were first detected in Vibrio cholera.
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Mechanisms of Intrinsic Antibiotic Resistance 1. Resistance Through Chromosomal Mutation Fluoroquinolones Almost all important fluoroquinolone resistance can be attributed to mutations within the drug's targets, DNA gyrase and topoisomerase IV. These complex molecules perform critical ATP-dependent functions during DNA replication. Each is comprised of several subunits: GyrA and GyrB for DNA gyrase and ParC/GrlA and ParE/GrlB for topoisomerase IV. The GyrA and ParC/GrlA proteins contain the DNAbinding functions and are targeted by fluoroquinolones (which are purely synthetic antibiotics), whereas GyrB and ParE/GrlB play the roles of ATP binding and hydrolysis and are inhibited by coumarin antibiotics. As the first step in developing resistance to fluoroquinolone, mutations occur in the DNA gyrase of the gram-negative bacteria, whereas the initial mutations occurring in the topoisomerase IV of the gram-positive bacteria result in initial resistance. Mutations that lead to fluoroquinolone resistance are found mainly in administrations, target the dihydropteroate synthase. Trimethoprim, introduced in 1968, inhibits dihydrofolate reductase and was the last structurally unique antibiotic approved prior to the release of linezolid in 2000. Mutations in the gene specifying dihydropteroate synthase reduce the binding affinity of the enzyme to sulfonamides, and have been found in laboratory samples of E. coli and Streptococcus pneumonia as well as in clinical isolates of Campylobacter jejuni and Haemophilus influenzae. Mutations in the gene specifying dihydrofolate reductase can result in the over-expression of an enzyme with a reduced binding affinity for trimethoprim, inducing a high degree of resistance to trimethoprim in E. coli and H. influenzae. [15] [16] [17] Tetracycline, Aminoglycoside, and Macrolide-LincosamideStreptogramin Antibiotics Antibacterial agents in tetracycline, aminoglycoside, and macrolide-lincosamide-streptogramin (MLS) classes target ribosomes in order to inhibit the translation of RNA into proteins; that is why chromosomal resistance through chromosomal mutation is not common. Tetracyclines and aminoglycosides interact with 16S rRNA (rrs), and the MLS family bind to 23S rRNA (rrl). In most bacteria, multiple rrs and rrl operons are present, and susceptibility caused by each of these targets can be dominant, making resistance difficult to achieve without a mutation in all or a majority of the other operons. However, in organisms with low rRNA (rrn) copy numbers, chromosomal mutations that cause resistance have appeared. Tetracycline resistance caused by a point mutation in Propionibacterium acnes (3 rRNA operons) and Helicobacter pylori (2 copies of rrn) has been recorded. Mutations in rrs lead to resistance to amikacin and kanamycin and alterations in small ribosome protein S12 (rpsL) or rrs affecting streptomycin (all aminoglycoside drugs) susceptibility in clinical M. tuberculosis (1 rrn operon) have been reported. The emergence of resistance the quinolone resistance-determining region (QRDR) of GyrA and ParC/GrlA. In general, bacterial isolates that are highly resistant to fluoroquinolone carry multiple QRDR mutations as well as other mechanisms for fluoroquinolone resistance such as drug efflux pumps.
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Rifampicin
Rifampicin is a bacterial drug that stops transcription by interacting with RpoB in the RNA polymerase beta subunit. Although combination therapies including rifampin or rifapentine, isoniazid, pyrazinamide, ethambutol, and streptomycin, are still the primary choices for the treatment of M. tuberculosis-induced infections, significant drug resistance still occurs in the rifampin-binding region of rpoB through point mutations at a frequency of 1×10 -6 . 13, 14 Sulfonamides and Trimethoprims Sulfonamides, which are the first antimicrobial compounds and were manufactured in large scales in 1935 for clinical to erythromycin (a macrolide) caused by mutant rrl in S. pneumonia (4 copies of rrn) has also been reported. Moreover, mutations in the large ribosome protein L4 (rplD) have also been shown to alter MLS susceptibility. Ketolides, introduced into clinical applications 2 decades ago, are designed to reduce macrolide resistance; nonetheless decreased resistance to telithromycin (a ketolide) has been found in S. pneumonia with mutations in rrl, rplD, and large ribosome protein L22 (rplV). Previous studies have shown that mutations in L22 also affect quinupristin-dalfopristin (streptogramins that act individually in a bacteriostatic manner) susceptibility by affecting their synergistic relationship, which is of high importance to the combination's bactericidal mechanism of action.
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Oxazolidinones Linezolid (another inhibitor of protein production) has been approved as an agent to treat methicillin-resistant S. aureus and vancomycin-resistant enterococci (VRE) infections. The availability of both intravenous and oral formulations of these antibiotics makes them applicable for use both in-and out-of-hospital settings. Resistance to linezolid in laboratory studies has been related to point mutations in rrl in S. aureus and Enterococcus faecalis. Linezolid-resistant clinical isolates of Staphylococcus epidermidis, S. aureus, Streptococcus oralis, Enterococcus faecium, and E. faecalis have been confirmed and documented, and many of them bear rrl mutations. Similar to fluoroquinolones, the level of resistance in S. aureus increases extensively with mutations in multiple rrl alleles.
Lipopeptides
Daptomycin (a drug acting on bacterial membranes) was approved by the Food and Drug Administration (FDA) in 2003. Although it has been successfully used for treating infections caused by bacteria, treatment failures have also been reported. Studies have shown that mutations in multiple chromosomal loci (e.g., mprF, yycG, rpoB, and rpoC) affect daptomycin susceptibility. [27] [28] [29] 2. Resistance Through Genomic Duplications Another common mechanism for drug resistance is gene amplification resistance, which leads to the overexpression of multidrug transporters and drug targets. For example, largescale duplications of the acrAB locus of the mutant bacteria E. coli have been detected in the presence of tetracycline, and it results in the over-expression of the acrAB efflux pump, creating a kind of bacterial MDR phenotype. The mutants, however, are unstable and revert to the wild-type phenotype in the absence of the drug. Previous studies have also shown that genomic amplification affects susceptibility to methicillin in S. aureus. It is expected that the use of gene duplication as a mechanism of resistance is increasing among bacterial isolates. However, in this case, the likely phenotype will be an unstable form of resistance (Table 2) . 18, 30, 31 Mechanism of Acquired Antibiotic Resistance 1-Enzymatic Drug Modification Enzymes that modify antibacterial drugs are divided into 2 general classes: those such as β-lactamases that degrade antibiotics, and others that perform chemical transformations (including the macrolide and aminoglycoside-modifying proteins). 33 
β-Lactam Antibiotics
There are hundreds of β-lactamases. Most resistance is caused by genes located on plasmids and transposons; others are chromosomal and provide intrinsic resistance. β-lactamases are classified using indicators based on function (the system of Bush-Jacoby-Medeiros) or structure (Ambler classification), but in general, they are broadly divided into enzymes with a serine in the active site and those that require a metal ion cofactor. The Ambler classification system divides Figure 4 ).
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Aminoglycosides A large number of aminoglycoside-modifying enzymes are produced by genes located on transferable elements. This type of resistance is accomplished with proteins that N-acetylate (acetyltransferase), phosphorylate (phosphotransferase), and adenylate (nucleotidyltransferase) aminoglycosides. The acetyltransferases are able to modify tobramycin, gentamicin, netilmicin, and amikacin; the nucleotidyltransferase proteins alter the activity of tobramycin; and the phosphotransferases affect amikacin susceptibility. Many of the aminoglycosidemodifying enzymes are found on integrons and other mobile genetic elements. For example, three acetyltransferase genes were found on a class 1 integron from P. aeruginosa that causes resistance to carbapenems and sulfonamides.
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Macrolide-Lincosamide-Streptogramin Antibiotics
There are a number of inactivating enzymes that affect MLS antibiotics. Their genes encode esterases, hydrolases, glycosylases, phosphotransferases, nucleotidyltransferases, and acetyltransferases and are found less frequently than efflux and ribosome-modifying genes in clinical isolates. Esterases act on 14-(e.g., erythromycin) and 15-(e.g., azithromycin) membered macrolides; the hydrolases affect streptogramin B drugs. Acetyltransferases inactivate streptogramin A antibiotics, and nucleotidyltransferases produce resistance to lincosamides (e.g., clindamycin). Phosphotransferases modify 14-, 15-, and 16-membered macrolides by modifying their characteristics.
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Chloramphenicol
The acetyltransferases that inactivate chloramphenicol are the most common resistance mechanisms for these antibiotics and are divided into two types, A and B enzymes, both of which act as homotrimers but are not related based on amino acid sequence analyses. The type B enzymes are also termed xenobiotic acetyltransferases and seem to share an evolutionary lineage that includes some streptogramin-inactivating enzymes found in enterococci and staphylococci.
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Tetracyclines A flavin-dependent monooxygenase, designated tet(X), has been identified in Bacteroides fragilis that acts on older tetracyclines (such as tetracycline, oxytetracycline, and chlortetracycline) as well as newer compounds (such as doxycycline, minocycline, and tigecycline). This enzyme catalyzes regioselective hydroxylation to inactivate its initial target, but the products of this enzyme are unstable at a physiological PH. Although a related tet(X)-like gene in P. aeruginosa has been reported, the presence and interference of this gene have not been reported in tetracycline-resistant clinical isolates. 43, 44 2. Altered, Substituted, and Protected Drug Targets β-Lactam Antibiotics The first penicillin-resistant S. aureus, identified in the mid- . In addition to mecA, SCCmec contains the mecR1-mecI regulatory loci and encodes enzymes that are involved in site-specific recombination. S. aureus uses multiple PBPs during cell wall biosynthesis under normal circumstances. One of them, PBP2, is a bifunctional enzyme with transpeptidase and transglycosylase activities. When methicillin-resistant S. aureus is exposed to methicillin, PBP2 acts as the transglycosylase, while using its transpeptidase activity to produce resistance to nearly all β-lactam antibiotics.
Removal of the transglycosylase function of PBP2 leads to β-lactam susceptibility and demonstrates the importance of both functions of the enzyme. 45 Glycopeptides Glycopeptides (including vancomycin and teicoplanin) interact with bacterial peptidoglycan precursors. Resistance to glycopeptides in gram-positive cocci is another example of an altered drug target. In enterococci, acquired glycopeptide resistance is a trait attributable to VanA, B, D, E, and G phenotypes, while VanC is responsible for the intrinsic resistance. VanA and VanD cause resistance to both vancomycin and teicoplanin, whereas the others produce resistance to vancomycin alone. The resistance phenotype is accomplished using multiple proteins produced by gene clusters and each result in the production of a modified peptidoglycan. Of the many drug-resistance indexes recently known, the glycopeptide resistance inductor is probably the most complex one. 47 The activity of many enzymes produced by the gene cluster is involved in causing glycopeptide resistance. Both a racemase and a dehydrogenase can result in the production of serine ( In recent years, the enterococcal vanA gene cluster has made its way into methicillin-resistant S. aureus and manifested an extensive vancomycin resistance. In all cases, the resistance elements are located on the plasmid of Tn1546 transposon. Vancomycin-resistant E. faecalis and methicillin-resistant S. aureus were also obtained from patients bearing vancomycin-resistant S. aureus, and each contained identical plasmids, except for the presence of Tn1546 in the isolate of vancomycin-resistant E. faecalis. It is assumed that the plasmid from E. faecalis was the vehicle for vanA entry into S. aureus and that the vanA gene cluster was subsequently transferred by means of transposition into the S. aureus plasmid (Figure 6 ).
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Tetracyclines and MLS Antibiotics
The most prevalent forms of resistance to tetracyclines in the clinic are drug efflux and ribosome protection. Ribosome protection factors have sequence similarity to bacterial elongation factors (EF-G an EF-Tu). They also possess GTPase activity and facilitate the release of tetracycline from the ribosome in a manner that requires energy. In Megasphaera elsdenii, a mosaic gene containing 2 ribosome protection factors (TetO and TetW) has been reported. Moreover, the tet(P) element of Clostridium perfringens creates both ribosome protection and efflux mechanisms in an overlapping genetic unit. 52 Drug binding within the MLSK (macrolide-lincosamide-streptogramin-ketolide) family to 23S rRNA is affected by erm (erythromycin resistance methylase or erythromycin ribosome methylation) gene products. These mechanisms represent the predominant macrolide resistance mechanisms in Europe and South Africa. Currently, there are 34 different classes of Erm proteins (http://faculty.washington.edu/marilynr/), and each acts by methylating a single adenine in the E. coli 23S rRNA (at position A2058). Methylation results in the demonstration of the MLSa phenotype, which causes resistance to 14-, 15-, and 16-membered lincosamides and streptogramin B. In staphylococci, agents like erythromycin and azithromycin induce erm expression, but 16-membered macrolides do not. Permanent erm expression in some clinical and laboratory strains causes telithromycin resistance.
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Sulfonamide and Trimethoprim Antibiotics
The activities of the sulfonamides and trimethoprim are also affected by acquired genes specifying enzymes that are insensitive to drug inhibition. Sul1 and sul2 are the main elements of clinical resistance to sulfonamide, whereas sul3 was found to be prevalent in farm animals. In contrast, more than 20 trimethoprim resistance genetic elements (numbered chronologically from dfr1) have been documented. The genes specifying the sulfonamide-insensitive dihydropteroate synthases are present on class 1 integrons (sul1) or plasmids (sul2), whereas dfr variants (with dfr1 being the most common in gram-negative bacteria) move from bacterium to bacterium on class 1 and 2 integrons. The dfr1 gene is located on the Tn7 transposon, facilitating its penetration into the E. coli chromosome.
Fluoroquinolones
Plasmid-specified qnr elements cause an unusual mechanism of decreased fluoroquinolone susceptibility. Variants of the qnr element, which were first identified in K. pneumoniae, The qnr and MfpA genes cause only low levels of resistance to fluoroquinolones by themselves, but they can increase such resistance when combined with other effective mechanisms.
Efflux Systems and Porins
Efflux pumps were first described as a kind of antibiotic resistance mechanisms for tetracyclines; now, however, they are described as a general and effective mechanism of resistance in many bacteria. Most of the proteins which produce the efflux pumps belong to five different families: the resistance-nodulation-division (RND), major facilitator (MF), small multidrug resistance (SMR), ATP-binding cassette (ABC), and multidrug and toxic compound extrusion (MATE) (Figure 7) . Efflux is driven forward by proteins in the RND, SMR, MF, and MATE families using the proton and sodium-motive force, and therefore is referred to as a secondary transport; however, the ATP hydrolysis drives the efflux forward on primary transporters (ABC). Efflux proteins also fall into two general categories. Some of them, such as tetracycline (Tet) 26 . A by expressin S. aureus, in library that behind a tet identification An alter targets is to i virulence. Th that it can id the rapid synthesis of large numbers of drug candidates for evaluation in high-throughput screens.
Resistance as a clinical problem
There are several molecular mechanisms by which bacteria can become antibiotic resistant (BOX 1), all of which result from the reduced concentration or reduced activity of antibiotics in the bacterial cell 11 . However, regardless of the underlying molecular mechanism, several other factors influence how soon a particular resistant strain becomes a clinical problem 12 . These factors include rates of mutation 13, 14 , the frequency of the LATERAL GENE TRANSFER of resistance determinants 15, 16 , the intensity of antibiotic usage in hospitals and the community 17, 18 , the impact of antibiotic use in agriculture • Mutations that upregulate the expression of transmembrane efflux pumps can reduce the concentration of antibiotic in the bacterial cell. In many cases, efflux pumps can pump out several different antibiotics causing a multidrug-resistance phenotype 137, 138 .
• Enzymes that modify, cleave or otherwise inactivate an antibiotic are another common cause of resistance. The most important example clinically is the widespread occurrence of β-lactamases that cleave the β-lactam ring of β-lactam antibiotics 9 .
• Finally, the antibiotic target can be altered (by mutation 139, 140 , recombination 141 or replacement with an alternative target as happens with vancomycin resistance in enterococci 142 ) such that the affinity of the antibiotic for its target is reduced. profile and act on few factors or many factors in the same drug class. The rest, like the members of the RND family, which need multiple structural proteins to develop resistance, have the ability to bind multiple drug combinations that are not structurally interrelated, and thus produce vast numbers of resistance phenotypes. The structure of RND-based efflux pumps that are found in a number of gram-negative bacteria allows them to transport the drug from the cytoplasm as well as the inner and outer membrane of the cellular coating. 56 Tetracyclines Today, more than 20 types of tetracycline-related efflux pump proteins have been reported. They are classified into six different groups. These proteins contain either 12 fragments (like TetA-E in gram-negative bacteria) or 14 fragments (such as TetK and TetL in gram-positive bacteria) which bridge through cell membranes. The expression of Class 1 proteins is controlled by a transcription suppressor such as TetR. The antibiotic inactivates the suppressor and allows the expression of tetracycline efflux pumps. In another method, the production of TetK and TetL by tetracycline can be induced by mechanisms that involve reducing the translation rate or its re-initiation. In general, the tetracycline efflux pump is not a protected similar system.
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Macrolide-Lincosamide-Streptogramin Antibiotics MLS resistance is an ABC efflux protein that causes resistance to 14-and 15-membered macrolide antibiotics as well as streptogramin B in streptococci and staphylococci, but it does not affect clindamycin susceptibility. In staphylococci, the MsrA affiliates (VgaA and VgaB) are located on the plasmid. VgaA causes resistance to streptogramin A and lincosamides, and VGAB also develops the pristinamycin susceptibility (a combination of streptogramin A and B antibiotics). The Mef efflux transporters, which are the dominant macrolideresistance proteins in the United States, frequently and effectively act against 14-and 15-membered macrolides in Streptococcus; but strains expressing these proteins are susceptible to 16-membered macrolides, lincosamides, and streptogramin B. E. faecalis is normally resistant to quinupristin/dalfopristin, and this feature is attributed to the lsa gene, which encodes a streptogramin efflux protein belonging to the ABC family, since lsa mutation-induced inactivation causes quinupristin/dalfopristin susceptibility in this bacterium. Studies on efflux proteins have shown that eliminating an efflux system makes the bacteria susceptible to antibiotics even in the presence of chromosomal mutations reducing drug-binding affinity.
59,60
Fenicols
Chloramphenicol and florfenicol are extended-spectrum antibiotics that are used in human clinical treatments (chloramphenicol) and animals (florfenicol). Considering the toxic effects (irreversible anemia), the current use of chloramphenicol is restricted to the treatment of some severe fatal infections such as bacterial meningitis in patients who are allergic to penicillin. Fenicol-specific efflux proteins have been reported in a number of important clinical bacteria and fall into eight different groups (E-1 to E-8). Overall, these proteins produce higher levels of resistance to multi-drug efflux proteins (referred to below), and members of the E-3 and E-4 groups produce resistance to both fenicols.
Multi-Drug Resistance Efflux Systems
In the past, it was thought that the envelope of gram-negative bacteria, as a strong inhibitor of drug penetration, affected antibiotic susceptibility. Later studies have shown, however, that most antibacterial agents effectively penetrate gramnegative bacteria, while they fail to achieve intracellular targets due to the presence of active efflux pumps in their membrane. The intrinsic resistance of gram-negative bacteria, such as E. coli, P. aeruginosa, Acinetobacter, Streptococcus mutans, Burkholderia cepacia, and Acinetobacter species, is attributed to the expression of RND efflux pumps. 61 Tigecycline, approved by the FDA in 2005, has poor effectiveness against P. aeruginosa, Proteus mirabilis, Morganella morganii, and Klebsiella pneumonia which is attributed to RND systems. Studies have shown that the removal of ArcA orthologous in Morganella morganii, MexXY-OprM in P. aeruginosa, and ArcB orthologous in P. mirabilis increases the susceptibility to tigecycline by 16 to 133 times, while the removal of ArcB and ArcEF in E. coli exerts a more balanced effect (4 times). [62] [63] [64] The bacillus multidrug resistance transporter (Bmr) in Bacillus subtilis and Qac (quaternary ammonium compound) in S. aureus are 2 MDR efflux proteins (major family members of MF) that were first detected and described in grampositive bacteria. Like many members of the RND family in gram-negative bacteria, Bmr is expressed continuously and thus provides intrinsic resistance to chloramphenicol and fluoroquinolones. Blt is another MDR efflux pump in Bacillus subtilis, which also contains spermidine in its list of target compounds. It is now thought that the natural function of Blt is to facilitate the removal of polyamines from the cell. The staphylococcal Qac systems provide resistance to antiseptics and disinfectants (e.g., quaternary ammonium compounds, chlorhexidine, and diamidines). Unlike most other MDR efflux proteins, these are specified on plasmids, a feature that facilitates their dissemination (Table 3) . [65] [66] [67] [68] Porins As mentioned previously, the outer membrane of the gramnegative cell envelope is a barrier to both hydrophobic and hydrophilic compounds. In order to circumvent this permeable barrier, these organisms have evolved porin proteins (e.g., OmpF in E. coli and OprD in P. aeruginosa) that function as "nonspecific" entry and exit points for antibiotics and other small-molecule organic chemicals. Imipenem (and to a lesser extent meropenem) and basic amino acids pass through OprD; mutations that decrease expression of the porin contribute to clinical imipenem resistance. Studies have shown that the expression of OprD and the MexEF-OprM efflux system is co-regulated, leading to the development of resistance to carbapenems and other MexEF-OprM-dependent compounds in mutants where the expression of OprD and the efflux pump has been altered. In 1997, Hiramatsu et al identified a clinical S. aureus isolate in Japan that exhibited an intermediate level of resistance to vancomycin. Shortly thereafter, other bacteria with a glycopeptide-insensitive phenotype were identified in the United States. A prominent feature of the VISA isolates is the presence of a thickened cell wall. It is presumed that this property traps vancomycin and prevents the antibiotic from reaching its target. In 2006, the same researchers found reduced susceptibility to daptomycin in VISA samples. 69, 70 Mutations that produce resistance to polymyxin B in P. aeruginosa presumably involve changes in the bacterial cell envelope that do not involve porins. In Salmonella enterica serovar Typhimurium, PmrAB (a two-component regulatory system) regulates resistance to polymyxin by modifying lipopolysaccharide and lipid A. The RosAB efflux system of Yersinia enterocolitica also affects susceptibility to polymyxin B.
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Conclusion
More than half a century has passed since the first antibiotics were introduced commercially. It did not take long for microbes to promote their resistance systems, and the widespread use of many antibacterial drugs provided ideal conditions for the spread of MDR organisms. Most of the initial research focused on identifying ways to avoid the inhibitory effects of these drugs. Researchers such as Esther and Joshua Lederberg characterized the random nature of mutational events causing resistance to streptomycin. Other researchers like Tsutomu Watanabe thought that mutation alone would not be sufficient for explaining the MDR phenotype. These studies showed that resistance transfer factors (RTFs), later called resistance (R) factors and then plasmids, would provide the basis for multiple drug resistance caused by "infective heredity". For bacteria, there is more than one way to evade a drug class, and today, many bacteria that continue to be unresponsive to all antimicrobial agents, even those they have not encountered previously, have been identified. Generally, bacteria adopt intricate strategies to avoid the lethal effects of antibiotics. Having an awareness of these mechanisms of resistance can help researchers design new drugs. As we face this critical problem, we need to be aware of and recognize the fluidity of the microbial genome and the ways in which resistance can appear by gene mutation or acquisition. Recognizing the potential for the emergence of resistance can give scientists a broader view for achieving deliberate discovery of novel compounds that will be needed to treat uncontrollable bacterial infections in the coming years. 73 
